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ABSTRACT
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in native kidney biopsies from
adults. In 2009, antibodies to the M-type receptor of phospholipase A2 (anti-PLA2R) were identified in idiopathic MN
patients, both within the kidney and in the circulation. The clinical course of idiopathic MN is variable and ranges from
spontaneous remission to end-stage renal disease. Clinical variables such as proteinuria levels, patient sex, age and renal
function at diagnosis have been associated with renal MN progression. In this editorial, we update the importance of anti-
PLA2R levels as a prognostic marker in idiopathic MN at the diagnosis of the disease.
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Membranous nephropathy (MN) is one of the most common
causes of nephrotic syndrome in native kidney biopsies from
adults. MN is uncommon in children and when diagnosed, the
disease is normally secondary and is associated with another
pathology such as autoimmune diseases [1]. The term MN
describes the histologic pattern identified on kidney biopsy. The
thickened appearance of the glomerular basement membrane
resulting in the name ‘membranous’ is a consequence of the an-
tibody/antigen deposits that accumulate below the epithelial
cell, the podocyte. The deposits and the extracellular matrix
form the characteristically named spikes, observed by Jones’ sil-
ver stain. The deposits themselves result in the fine granular
capillary loop pattern seen on immunofluorescence and the
subepithelial electron dense deposits observed by electron mi-
croscopy [2].
MN can be idiopathic MN (IMN) or primary, when a cause is
not identified (IMN), which accounts around 80% of cases, or
secondary MN (SMN) forms can be seen in the setting of autoim-
mune disease, neoplasia, infection and after being exposed to
some therapeutic agents [3]. In 2009, a seminal renal research
by Beck and colleagues first found that the antibodies to the M-
type receptor of phospholipase A2 (anti-PLA2R) were present in
IMN patients, both within the kidney (located on the podocyte
membrane) and in the circulation [4]. Interestingly, these
antibodies were not found in other glomerular diseases such as
focal segmental glomerulosclerosis and minimal change glo-
merulonephritis. Anti-PLA2R antibodies are most often of the
Immunoglobulin G4 (IgG4) subclass and co-localized with IgG4
in the fine granular pattern that is typical of MN [4].
Interestingly, the discovery of PLA2R allowed for retrospective
diagnosis of PLA2R-related MN in archived renal biopsies [5].
Studies from Hofstra and colleagues demonstrated in a
European patient cohort that the levels of circulating anti-PLA2R
revealed a strong correlation with clinical disease activity.
Their results suggest that the low or absent anti-PLA2R levels
after IMN treatment may indicate the remission of immunologic
activity, becoming a useful tool for monitoring disease activity
and subsequently predicting MN recovery and relapse.
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However, some studies suggest that anti-PLA2R levels maybe
different depending on the ethnicity; in this sense, in a
Japanese cohort with IMN observed a lower rate of anti-PLA2R-
positive patients [6].
The clinical course of MN presented a wider spectrum, from
spontaneous recovery, which accounts for 30–40% of patients to
massive proteinuria that progresses to chronic kidney disease
(CKD) [1]. At diagnosis, the nephrologist needs to detect patients
with IMN at risk for CKD progression, giving that the identifica-
tion of patients who will benefit of immunosuppressive treat-
ment. Proteinuria >8 g/day, male sex, >50 years of age, and renal
dysfunction at presentation were classically identified as a risk
factors for CKD progression in IMN. In the current study by the
Quintana group in a Spanish cohort of IMN [7], the authors dem-
onstrated that complete remission was not observed in IMN
patients with anti-PLA2R >40 IU/mL and was less frequently ob-
served in patients with proteinuria >8 g/day. In addition, patients
with high antibody levels had higher risk for developing end-
stage renal disease (ESRD), and the necessity of renal replacement
therapy was lower in patients with negative anti-PLA2R during
the follow-up. Interestingly, their study reinforces the important
role of anti-PLA2R in the clinical prediction of the IMN course at
the diagnosis and suggests that patients with high anti-PLA2R
levels (>40 UI/mL) and high proteinuria (>4 g/day) could benefit
from immunosuppressive treatment, whereas patients with low
anti-PLA2R levels (<40 UI/mL) and low proteinuria (<4 g/day)
could benefit from a longer period of follow-up with conservative
treatment [7] (see suggested treatment algorithm, Figure 1). In
concordance with their results, other studies and a recent meta-
analysis also demonstrated that IMN patients with anti-PLA2R at
renal biopsy presented high spontaneous remission rate with
conservative treatment [8, 9]. In the current study, Rodas and col-
leagues [7] took a step forward and demonstrated that the levels
of anti-PLA2R are clearly related to the IMN prognostic and subse-
quently may help to detect patients at risk for CKD progression.
In 2014, a second IgG-specific antibody for thrombospondin
type-1 domain-containing 7 A (THSD7A) was identified in adult
IMN. Around 2.5–5% of IMN patients presented anti-THSD7A,
corresponding to 8–14% of patients with negative anti-PLA2R
[10]. Of note, the presence of anti-THSD7A in MN patients has
been associated in 21% of patients with a malignant tumour
such as endometrial carcinoma and gallbladder carcinoma.
Interestingly, the carcinomatous cells also revealed increased
THSD7A protein expression, and the chemotherapy treatment
decreased anti-THSD7A and proteinuria in those patients with
secondary MN. Thus, the increase of anti-THSD7A may be an
immune mechanism response against the increase of THSD7A
protein within the malignant cells. As a consequence, some
authors recommend that when THSD7A-associated MN is diag-
nosed, an aggressive screening for cancer to diagnose secondary
MN should be performed [11].
Classically, the gold standard for MN diagnosis has been the
kidney biopsy. However, the recent discoveries in the last decade
suggest for the first time that kidney biopsy may not be required
in PLA2R-associated MN. This new approach for MN diagnosis is
based on the high specificity of the PLA2R antibody (Ab), which
reaches 100% [12], and may be of great interest in patients with
relative contraindications for kidney biopsy such as single kidney
or bleeding disorder patients. Recently, PLA2R-associated MN has
also been detected in patients with secondary MN, mainly in hep-
atitis and sarcoidosis patients, indicating that further studies are
needed to elucidate new markers of IMN [13].
In conclusion, the study by Rodas et al. demonstrates the im-
portant role of anti-PLA2R as a tool to predict IMN course and
prognosis early on, at the moment of diagnosis. The authors
suggest that the anti-PLA2R and proteinuria levels may clearly
help to detect patients at risk for ESRD progression (who will
benefit from immunosuppressive treatment) and spontaneous
remission patients (who will benefit from conservative therapy)
[7]. Anti-PLA2R levels <40 IU/mL at MN diagnosis may become a
useful tool for detecting patients who will benefit from conser-
vative treatment, and subsequently avoid the secondary effects
of immunosuppressive treatment in those patients.
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